Photo Credit: Daria Bulgakova

The following is a summary of “Novel Electrotrichogenic Device Promotes Hair Growth in Men With Androgenetic Alopecia: A Pilot Study,” published in the April 2025 issue of Journal of Cosmetic Dermatology by Jellard et al. 

Androgenetic alopecia (AGA) was recognized as the leading global cause of hair loss, with existing FDA-approved treatments often yielding side effects or limited effectiveness.  

Researchers conducted a retrospective study to evaluate the efficacy and safety of the niostem device in male individuals with AGA.  

They enrolled 21 male individuals with AGA who used the niostem device daily for 30 minutes over 6 months and ensured no participants had used anti-hair loss products in the 6 months prior to the study. The hair density, thickness, and terminal hair counts were measured using trichoscopy at baseline, 3 months, and 6 months and collected patient-reported outcomes and monitored adverse events (AEs).  

The results showed a 12% increase in total hair density at 3 months, a 19.3% increase at 6 months, an 8.8% rise in hair thickness over 6 months, and a consistent improvement in terminal hair density with visible growth; no AEs were observed.  

Investigators concluded that the niostem device had demonstrated a significant increase in hair density and hair thickness in male patients with androgenetic alopecia (AGA) without adverse events, and that it may serve as a supportive option alongside hair transplantation, although further large-scale studies were warranted. 

Source: onlinelibrary.wiley.com/doi/10.1111/jocd.70202